drugset / Trial / NCT05931393
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.
Timeline
- Start
- 2023-12-20
- Primary completion
- 2026-09-01
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 80 mg | Oral |